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A B S T R A C T
Background: Abdominal compartment syndrome (ACS) causes severe pathology in the cardiovascular,
renal and pulmonary systems. Recent studies showed that pentoxifylline (PTX) has effects on increasing
tissue oxygenation, healing capillary reﬁll and reducing superoxides and hydroxyl radicals by inhibiting
xanthine oxidase. In this study, our aim was to study the effects of PTX on free oxygen radicals and oxi-
dative damage in rats with ACS model.
Materials and methods: ACS model was created in 32 male Wistar-Albino-rats, which were random-
ized into one of the four study groups: Group A (n:8), having ACS; Group B (n:8), having ACS and receiving
PTX (50 mg/kg/day) intraperitoneal for 10 days; Group C (n:8), receiving PTX (50 mg/kg/day) intraperi-
toneal for 10 days without having ACS; Group D (n:8), having no ACS and not receiving PTX. On the 11th
day blood samples were collected to measure alanine-amino-acid-transferase (ALT) and aspartate-amino-
acid-transferase (AST) in the heart, malondialdehyde (MDA), myeloperoxidase (MPO) and glutathione
(GSH) in the liver, lung and small bowel. Histopathologic injury scoring was done.
Results: Groups were compared in pairs. Group A compared to Group B: ALT increase, liver MDA, lung
GSH and MPO decrease were statistically meaningful in Group B. Group A compared to Group C: ALT
and liver MPO decrease and liver MDA increase were statistically meaningful in Group A. Group B com-
pared to Group C: ALT increase, MDA and GSH decrease in the lung were statistically meaningful in Group
B. Group B compared to Group D: ALT and MPO increase in the small bowel and MPO decrease in the
lung were statistically meaningful in Group B. Group A had the highest histopathologic injury scoring.
Conclusion: Histopathologically conﬁrmed pentoxifylline was effective in the treatment of ACS in these
rat models.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Abdominal compartment syndrome (ACS) is an independent
marker for mortality and is associated with an increased rate of mul-
tiple organ dysfunction. ACS is deﬁned as increased intra-abdominal
pressure equal to or more than 20 mmHg [1]. The pathophysiol-
ogy of ACS is directly related to the increased intraabdominal
pressure (IAP). Increased IAP compresses the thoracic cavity through
the diaphragm and reduces ventilation. Increased IAP compresses
the vena cava and decreases the cardiac output by decreasing venous
return. Decrease in cardiac output and venous return cause de-
creased kidney, splenic and liver perfusion. This multi-organ hypo-
perfusion causes pathologies as systemic inﬂammatory response and
adult respiratory distress syndrome [2–6]. IAP may increase with
various reasons like trauma, abdominal surgery, laparoscopic surgery,
over ﬂuid replacement, severe retroperitoneal hemorrhage, acute
renal failure, acute pancreatitis, retroperitoneal malignancies, and
massive ascites [6,7].
Ischemia is deﬁned as insuﬃcient arrive or interruption of blood
ﬂow to certain tissues or organs [8]. Hypoxia-related tissue damage
occurs. Prolonged ischemia impairs the structural integrity of cells
and cell death may occur [8,9]. Reperfusion is tissue restoration of
blood ﬂow [8,10]. Previous studies reported that severity of the tissue
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injury varies according to the duration and grade of the ischemia
[11,12]. Tissue injury occurs in the ischemic period and also in the
reperfusion period. When ischemic tissue blood ﬂow is resup-
plied, free oxygen radicals are released from polymorphonuclear
leukocytes in the tissue, and tissue damage is exacerbated [8,10,13].
Ischemia/ reperfusion damage is not only seen in the affected tissue,
but also in other organs due to systemic inﬂammatory response
[14,15]. To limit the potential damage of free oxygen radicals, en-
zymatic and non-enzymatic antioxidants are released from the cells.
Pentoxifylline is a methlxanthine derivative drug, similar
to theophylline. Pentoxifylline shows its effect by inhibiting phos-
phodiesterase enzymes and this increases the cyclic AMP on
polymorph nuclear leukocytes and decreases the free oxygen radical
production [16]. It is commonly used to improve microvascular cir-
culation in patients with vascular insuﬃciency, because it reduces
platelet aggregation [17]. Recent studies showed that pentoxifylline
inhibits xanthine oxidase, thus reduces superoxide (SO) and hy-
droxyl (OH) radicals, heals capillary circulation and tissue
oxygenation. Besides it also inhibits free oxygen radicals and Phos-
pholipase A2, which increases prostacyclin release [17,18].
Harmful physiological changes that occur as a result of ACS clin-
ically affect most cardiovascular, renal and pulmonary systems.
Reduction in cardiac output, increase in peripheral resistance, oli-
guria, anuria and hypoxia may occur. Fatal organ failure may occur
in untreated cases. ACS working model experimentally carried out
is not possible except for animal.
We designed an animal model of ACS to study the effects of a
vasodilating agent, pentoxifylline, on the treatment of oxidative
damage caused by ACS.
2. Methods
This study was approved by the Animal Experiments Local Ethics
Committee of İstanbul University (Process number 2014/101). The
experiments were performed in adherence with the international
guidelines for the care and use of laboratory animals at the Labo-
ratory of Surgical Physiopathology.
The test subjects were randomly enrolled in one of the 4 study
groups. The rats were fasted before the surgery night. Rats were sub-
sequently anesthetized with ketamine hydrochloride 50mg/ml and
Xylazine hydrochloride 20mg/ml given intraperitoneally in a dosage
of 0.1 ml/100 g. Following this, the rats were ﬁxed in the supine po-
sition on a regularly disinfected and surgically draped operating table.
Model of ACS was stimulated by insertion of a 16 Gauge cannula
under sterile conditions into the peritoneal cavity and insuﬄation
of 20 mmHg CO2 for two hours. Ten days after this procedure the
rats were sacriﬁced. Blood samples were taken from the heart apex
for ALT and AST, and tissue samples were taken from the lung, liver
and small bowel.
Group A (n:8), having ACS. The rats were fasted before the surgery
night. Rats were subsequently anesthetized with ketamine hydro-
chloride 50 mg/ml and Xylazine hydrochloride 20 mg/ml given
intraperitoneally in a dosage of 0.1 ml/100 g. Following this, the rats
were ﬁxed in the supine position on a regularly disinfected and sur-
gically draped operating table. Model of ACS was stimulated by
insertion of a 16 Gauge cannula under sterile conditions into the
peritoneal cavity and insuﬄation of 20 mmHg CO2 for two hours.
Group B (n:8), having ACS and receiving pentoxifylline (50 mg/
kg/day) intraperitoneal for 10 days. The rats were fasted overnight
prior to surgery, and were subsequently anesthetized with ketamine
hydrochloride 50mg/ml and xylazine hydrochloride 20mg/ml given
intraperitoneally in a dosage of 0.1 ml/100 g. Following this, the rats
were ﬁxed in the supine position on a regularly disinfected and sur-
gically draped operating table. Model of ACS was stimulated by
insertion of a 16 Gauge cannula under sterile conditions into the
peritoneal cavity and insuﬄation of 20 mmHg CO2 for two hours.
After desuﬄation of the peritoneal cavity, pentoxifylline was given
(50 mg/kg/day) in one cc of 9% NaCl intraperitoneal for 10 days.
Group C (n:8), receiving pentoxifylline (50 mg/kg/day) intra-
peritoneal for 10 days without having ACS. The rats were fasted
overnight prior to surgery, and were subsequently anesthetized with
ketamine hydrochloride 50mg/ml and xylazine hydrochloride 20mg/
ml given intraperitoneally in a dosage of 0.1ml/100 g. Following this,
pentoxifylline was given (50 mg/kg/day) in one cc of 9% NaCl in-
traperitoneal for 10 days.
Group D (n:8) having no ACS and not receiving pentoxifylline
was the sham group. The rats were fasted overnight prior to surgery,
and were subsequently anesthetized with ketamine hydrochlo-
ride 50 mg/ml and xylazine hydrochloride 20 mg/ml given
intraperitoneally in a dosage of 0.1 ml/100 g.
32 Male Wistar rats (250–300 g) were purchased from the
İstanbul University, Institute of Experimental Medicine. Male rats
were preferred, becausemenstrual cycle may have affected the blood
test results.
All rats were stored in metal cages and maintained in 12-hour
dark/light cycle at a controlled temperature of 22 °C (±1). All rats
were fed with 21% protein food and fresh tap water, only rats to get
IAP will be unfed one day before. All cages were cleaned daily, 4
rats were put in a cage and the rats that were in the same group
were stored together.
All rats were sacriﬁced on the 11th day with high dose ketamine
and blood samples were collected to measure alanine-amino-acid-
transferase (ALT) and aspartate-amino-acid-transferase (AST) in the
heart, malondialdehyde (MDA) and glutathione (GSH) in the liver,
lung and small bowel. Histopathologic injury scoring was done in
the liver, lung and small bowel. All tissues were put in a cryotube
into the deep freezer at −80 °C after being washed at +4 °C phos-
phate buffer saline (PBS) and stored until the biochemical analysis.
Blood samples were taken from the heart apex while the heart rate
is presented and centrifuged at 3000–35,000 rpm for 15 minutes
in the dry yellow cap biochemistry tube. All samples of serum ob-
tained from each animal were put into three separate eppendorf
tubes and kept into the deep freezer at −80 °C again until the bio-
chemical analysis. MDA and GSH levels were used as oxidative stress
and MPO activity was used as inﬂammatory parameters.
2.1. ALT and AST analyses
ALT and AST analyses were measured with cobas 8000 e602
modular automatic analyzer (Roche Diagnostics, Mannheim,
Germany).
2.2. Glutathione (GSH) analysis
Dithiobisnitrobenzoic acid and GSH sulfhydryl (-SH) groupmakes
a reaction. The product of this reaction is yellow. For one mole -SH
group, one mole dithiobisnitrobenzoic acid forms and this product
has an absorbance at 412 nm at UV spectrophotometer. After ten
minutes of waiting at room temperature GSH activity was calcu-
lated according to the formula described in the manufacturer’s
protocol.
2.3. Myeloperoxidase (MPO) analysis
Tissue homogenites were made with 1 ml of cold
hexdecyltrimethly ammonium bromide buffer (50 mM KPO+ and
0.5% hexdecyltrimethly ammonium bromide [pH 6.0]). Homogenites
were sonicated on ice for 10 seconds, and centrifuged at 10,000 rpm
for 15 min at 4 °C. Twenty ml of supernatant solution was trans-
ferred into well plate, and 200 μl of O-dianisidine hydrochloride
solution at 37 °C (16.7mg O-dianisidine, 100ml: 90% water and 10%
50 mM KPO4 buffer + 0.0005% H2O2) was added. Immediately after
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this, solution optical density was read at 450 nm for three minutes.
Absorbance changes were calculated as (ΔA/min) and the results
were read nmol/mg protein/min.
2.4. Malondialdehyde (MDA) analysis
MDA is one of the end products of lipid peroxidation measured
by spectrophotometry with its complex thiobarbituric acid. This red
product has a peak absorption at 532 nm at UV spectrophotom-
eter. 0.2 ml of 10% of tissue homogenate was taken. 0.2 ml of 8.1%
sodium dodecyl sulfate, 5 ml 20% acetic acid, 1.5 ml of 0.8%
thiobarbituric acid and 0.6 ml distilled water were added on this
homogenate. This mixture was kept in boiling water bath for one
hour. After cooling, 1 ml of distilled water and 5 ml of butanol/
pyridine (15/1)mixturewere added and organic phasewas separated
by centrifuging. The homogenate free materials absorption was read
in a spectrophotometer at 532 nmwavelength. Calculation was done
with 1,1,3,3-tetraethoxypropan. Results expressed as nmol/g tissue
were identiﬁed.
2.5. Protein analysis
The amount of protein was determined by bicinchoninic acid
method in tissue homogenates prepared for MPO analysis. The ab-
sorption was read in well-plates in a spectrophotometer at 562 nm
wavelength at 37 °C for 30 minutes to the blind tube.
2.6. Histopathologic injury scoring of liver, lung and small bowel
For small bowel histopathologic injury score, one cm sample was
taken from 3rd, 5th and 7th 10-cm segment. These samples were
ﬁxed in formalin (10%, neutral buffered) for at least 24 hours. 3 mm
cross-sections were stained from paraﬃn bloc. Samples were ex-
amined and photographed under light microscope (Olympus BX61,
Japan). Histopathologic changes were evaluated in blinded manner
(blinded assessment of outcomes by one independent assessor). His-
topathologic injury scoring of small intestine was scored on a scale
of 0–8 as follows [19]: Grade 0, normal mucosa; grade 1, subepi-
thelial Gruenhagen space, capillary congestion; grade 2, extension
of the subepithelial space with a moderate epithelial lifting; grade
3, massive epithelial lifting down the sides of villi, few tips denuded;
grade 4, denuded villi; grade 5, loss (destruction) of villi, hemor-
rhage; grade 6, crypt layer injury; grade 7, transmucosal infarction;
grade 8, transmural infarction.
Histopathologic injury scoring of liver samples was scored on
a scale of 0–4 as follows [20]: Grade 0, minimal or no evidence of
injury; grade 1, mild injury characterized by cytoplasmic vacuol-
ization and focal nuclear pyknosis; grade 2, moderate injury
exhibiting cytoplasmic vacuolization, conﬂuent areas of hepato-
cyte ballooning but no frank necrosis, sinusoidal dilatation and
congestion, and blurring of intercellular borders; grade 3, moder-
ate to severe injury with areas of coagulative necrosis, cytoplasmic
hypereosinophilia, extensive sinusoidal dilatation and congestion;
grade 4, severe injury consisting of severe conﬂuent coagulative ne-
crosis, and disintegration of and hemorrhage into hepatic chords
leading to loss of tissue architecture.
Lung tissue injuries in blinded fashion are in accordance with
a scoring system modiﬁed by Kandilci et al. and Pirat et al. [21,22].
The scoring system is summarized in Table 1. Five parameters
(interstitial edema/inﬁltration, intra-alveolar edema/inﬁltration,
intra-alveolar hemorrhage, capillary congestion and airway epithelial-
cell damage) were evaluated for lung injury and the total lung injury
score was calculated.
2.7. Statistical analysis
Data were analyzed with IBM SPSS Statistics 15. Two group com-
parisons were performed by using Mann–Whitney U test and for
comparisons involving three or more groups, Kruskal–Wallis H test
was used. The correlation between the variables was calculated with
Fisher’s Exact Test. The value for signiﬁcance was considered p ≤ 0.05.
3. Results
Each group included in each analysis consists of eight rats except
for sham group. One rat in sham group perished before the end of
the experiment. The number of rats in each group included in each
analysis is respectively 8/32, 8/32, 8/32, 7/32.
During the study period one rat died in Group D. Laboratory and
histological ﬁndings for all Groups are shown in Table 2. As you may
see in Table 2, there were signiﬁcant differences for ALT, liver tissue
MDA, liver tissue MPO, lung tissue MPO and small bowel tissue MPO
(p < 0.05). Groups were compared in pairs in order to understand
which groups have differences with Mann–Whitney U test. Group
A compared to Group B: ALT increase, liver MDA, lung GSH andMPO
decrease were statistically meaningful in Group B (Table 3a). Group
A compared to Group C: ALT and liver MPO decrease and liver MDA
increase were statistically meaningful in Group A (Table 3b). Group
B compared to Group C: ALT increase, MDA and GSH decrease in
the lung were statistically meaningful in Group B (Table 3c). Group
B compared to Group D: ALT and small bowel MPO increase and
lung MPO decrease were statistically meaningful in Group B
(Table 3d).
Histopathologic injury scoring for all groups and for all rats is
shown in Table 4. There are signiﬁcant differences in all groups.
Groups were compared in pairs in order to understandwhich groups
have differences with Pearson Chi-Square test. In Group A histo-
pathologic injury score for liver, lung and small bowel was
signiﬁcantly higher than the other three groups (p < 0.05).
Any important adverse event did not happen on any experi-
ment group.
4. Discussion
Recent studies showed that pentoxifylline has effects on increas-
ing tissue oxygenation, healing capillary reﬁll and reducing
superoxides and hydroxyl radicals by inhibiting xanthine oxidase
in different clinical presentations like strangulated closed loop small
Table 1
Histological scoring system.
Parameters Scores
4 3 2 1 0
Interstitial edema/inﬁltration %75–100 involvement %51–75 involvement %26–50 involvement %1–25 involvement %0 involvement
Intra-alveolar edema/inﬁltration %75–100 involvement %51–75 involvement %26–50 involvement %1–25 involvement %0 involvement
Intra-alveolar hemorrhage %75–100 involvement %51–75 involvement %26–50 involvement %1–25 involvement %0 involvement
Capillary congestion %75–100 involvement %51–75 involvement %26–50 involvement %1–25 involvement %0 involvement
Airway epithelial-cell damage %75–100 involvement %51–75 involvement %26–50 involvement %1–25 involvement %0 involvement
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bowel, ischemic colitis or intestinal ischemia/reperfusion injury
[23–25]. According to our search for the literature, we have found
no study about the effect of pentoxifylline on ACS. In this study, our
aim was to study the effects of pentoxifylline on free oxygen radi-
cals and oxidative damage in rats with ACS model. Our study has
two components; ﬁrst we collected blood samples for serum levels
of ALT and AST and tissue samples from liver, lung and small bowel
for MDA, MPO and GSH levels, second we performed histopatho-
logic injury scoring for liver, lung and small bowel.
In Group A (ACS model without PTX), ALT increase, liver MDA,
lung GSH and MPO decrease were statistically meaningful to Group
B (ACS model with receiving PTX). ALT and AST are normally found
in serum at low levels [26]. Elevated transaminases mostly indi-
cate liver damage [27]. In our study ALT increase was meaningful
in Group A to Group B and AST levels were not. In recent studies
we know that if increase in serum AST levels was higher than serum
ALT levels, this should be due to occult muscle disease [28].
MDA is a signiﬁcant indicator of lipid peroxidation level andMDA
levels were higher in any injury [29]. In Group A, MDA levels were
statistically meaningfully higher than Group B. In ischemic
reperfusion model the effect of PTX was inhibition of platelet-
activating factor (PAF) and we believe that PTX had its protective
effect by this way [30]. GSH is a tripeptide antioxidant molecule that
helps in reduction of oxidative stress and can be used as oxidative
injury indicator [31]. In our study lung GSH levels were higher in
Group A than in Group B (p < 0.05). Tissue MPO activities are con-
sidered to indicate oxidative stress. In our study lung tissue MPO
activity was signiﬁcantly lower in Group A than in Group B andMPO
activity in liver or small bowel was not meaningful. These results
show us that PTX has a protective effect on oxidative stress or in-
ﬂammatory process in lung but has minimal effect in liver and small
bowel by laboratory ﬁndings. When we look at the histopatho-
logic injury score, this conclusion may change.
In Group A histopathologic injury score for liver, lung and small
bowel was signiﬁcant higher than the other three groups and these
results show us that PTX has a real effect on preventing oxidative
stress. We believe that this difference was due to the small sample
size (n:8), and as sample size increases, the statistics may be more
meaningful.
All funding was provided by the surgeons.
5. Conclusion
In conclusion ACS causes oxidative injury on liver, lung and small
bowel. PTX prevents/overcomes this injury with its antioxidant prop-
erties according to the histopathologic injury score and protects from
oxidative stress injury. According to our results we may say that
larger sample sizes are necessary for a clean conclusion.
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Table 2
Laboratory ﬁndings and P value for all groups.
Group Group A (ACS) Group B (ACS +
pentoxifylline)
Group C (pentoxifylline
without ACS)
Group D
(sham)
Total
ALT (p < 0,0001) 48,66 ± 4,19 76,96 ± 16,97 63,4 ± 10,93 58,41 ± 8,68 61,97 ± 14,99
Min: 44,3 Min: 50,3 Min: 48,2 Min: 42,9 Min: 42,9
Max: 53,4 Max: 101,7 Max: 81,5 Max: 68,9 Max: 102
AST (p: 0,135) 108,37 ± 31,67 134,47 ± 35,41 105,8 ± 19,34 107,5 ± 15,02 114,24 ± 28,41
Min: 82,6 Min: 88,7 Min: 80,6 Min: 85,5 Min: 80,6
Max: 166 Max: 182,9 Max: 138,2 Max: 132 Max: 183
Liver tissue MDA nmol/g (p < 0,0001) 150,48 ± 36,04 90,39 ± 29,85 88,54 ± 18,55 78,98 ± 12,75 102,84 ± 38,18
Min: 108,4 Min: 46,8 Min: 55,8 Min: 55,2 Min: 46,8
Max: 211 Max: 134,9 Max: 115,4 Max: 91,7 Max: 211
Liver GSH micromolg/tissue (p: 0,293) 5,32 ± 3,15 6,47 ± 2,16 8,86 ± 4,71 7,76 ± 4,65 7,08 ± 3,84
Min: 2,66 Min: 4,11 Min: 3,96 Min: 2,36 Min: 2,36
Max: 12.7 Max: 10,83 Max: 17,41 Max: 15 Max: 17,4
Liver MPO nmol/mg/protmin (p: 0,008) 15,1 ± 8,03 28,82 ± 14,96 40,12 ± 17,41 31,03 ± 10,48 28,69 ± 15,66
Min: 5,89 Min: 10,2 Min: 19,9 Min: 13 Min: 5,89
Max: 29,8 Max: 48,33 Max: 66,37 Max: 45 Max: 66,4
Lung MDA_ nmolg/tissue (p: 0,219) 33,46 ± 14,57 30,87 ± 8,38 41,85 ± 11,07 36,52 ± 6,04 35,65 ± 10,93
Min: 23,57 Min: 15,4 Min: 29,8 Min: 28,1 Min: 15,4
Max: 68,3 Max: 42,16 Max: 64,77 Max: 43,5 Max: 68,3
Lung GSH micromol/g/tissue (p: 0,074) 0,37 ± 0,15 0,28 ± 0,02 0,48 ± 0,21 0,58 ± 0,38 0,42 ± 0,24
Min: 0,1 Min: 0,23 Min: 0,23 Min: 0,2 Min: 0,1
Max: 0,63 Max: 0,31 Max: 0,9 Max: 1,13 Max: 1,13
Lung MPO/nmolmg/protmin (p: 0,033) 25,70 ± 21,78 6,46 ± 3,17 14,51 ± 9,02 13,14 ± 4,3 15,01 ± 13,66
Min: 5,38 Min: 2,32 Min: 4,3 Min: 5,76 Min: 2,32
Max: 68,5 Max: 11,59 Max: 28,88 Max: 18,5 Max: 68,5
Small bowel MDA nmolg/tissue (p: 0,272) 25,75 ± 6,52 21,85 ± 6,04 25,17 ± 8,71 19,75 ± 4,06 23,24 ± 6,74
Min: 17,64 Min: 13,8 Min: 13,2 Min: 15,4 Min: 13,2
Max: 37,8 Max: 29,18 Max: 37,84 Max: 25,3 Max: 37,8
Small bowel GSH micromolg/tissue (p: 0,245) 0,88 ± 0,31 1,42 ± 0,59 1,68 ± 1,46 0,97 ± 0,61 1,25 ± 0,89
Min: 0,35 Min: 0,6 Min: 0,35 Min: 0,25 Min: 0,25
Max: 1,3 Max: 2,46 Max: 4,21 Max: 2,01 Max: 4,21
Small bowel MPO nmolmg/protmin (p: 0,007) 20,90 ± 10,69 13,86 ± 4,45 15,42 ± 10,06 5,38 ± 2,34 14,16 ± 9,29
Min: 11,64 Min: 5,98 Min: 4,33 Min: 2 Min: 2
Max: 35,9 Max: 17,54 Max: 36,79 Max: 8 Max: 36,8
Results are in Mean ± Standard Deviation, Std.D: Standard Deviation, Min: Minimum, Max: Maximum, ALT: Alanine-amino-acid-transferase, AST: aspartate-amino-acid-
transferase. (Kruskal–Wallis-H p < 0,05).
Numbers (p < 0,05) were written in bold.
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Lung GSH micromol/g/tissue 22,00 0,328
Lung MPO/nmolmg/protmin 24,00 0,442
Small bowel MDA nmolg /tissue 30,50 0,878
Small bowel GSH micromolg/tissue 20,50 0,234
Small bowel MPO nmolmg/protmin 25,00 0,505
(c)
ALT 4,00 0.002
AST 30,00 0,878
Liver tissue MDA nmol/g 2,00 0,01
Liver GSH micromolg/tissue 14,00 0,65
Liver MPO nmol/mg/protmin 3,00 0,001
Lung MDA_ nmolg/tissue 14,00 0,065
Lung GSH micromol/g/tissue 22,00 0,328
Lung MPO/nmolmg/protmin 24,00 0,442
Small bowel MDA nmolg /tissue 30,50 0,878
Small bowel GSH micromolg/tissue 20,50 0,234
Small bowel MPO nmolmg/protmin 25,00 0,505
(d)
ALT 9,50 0,029
AST 15,00 0,152
Liver tissue MDA nmol/g 18,00 0,281
Liver GSH micromolg/tissue 27,00 0,955
Liver MPO nmol/mg/protmin 26,00 0,867
Lung MDA_ nmolg/tissue 16,50 0,189
Lung GSH micromol/g/tissue 13,00 0,094
Lung MPO/nmolmg/protmin 6,00 0,009
Small bowel MDA nmolg/tissue 23,00 0,613
Small bowel GSH micromolg/tissue 15,50 0,152
Small bowel MPO nmolmg/protmin 4,00 0,004
Numbers (p < 0,05) were written in bold.
Table 4
Histopathologic injury scoring for all groups.
Group Small bowel
injury score
Liver injury
score
Lung injury
score
A 1 5,00 1,00 4,00
2 6,00 3,00 4,00
3 6,00 2,00 3,00
4 7,00 3,00 3,00
5 6,00 3,00 3,00
6 4,00 2,00 3,00
7 7,00 2,50 3,00
8 7,00 3,00 3,00
B 1,00 1,00 1,50 2,00
2,00 2,00 1,00 3,00
3,00 1,50 0,50 2,50
4,00 1,00 0,50 2,75
5,00 0,50 1,00 2,50
6,00 0,50 1,00 1,00
7,00 1,00 0,50 1,50
8,00 3,00 1,00 2,50
C 1,00 1,00 0 1,50
2,00 0 0 1,50
3,00 1,00 0 2,00
4,00 0 0,50 1,00
5,00 0 0,00 1,50
6,00 1,00 0,50 1,00
7,00 0 0,50 1,25
8,00 0 0 2,00
Total 8 8 8
D 1,00 0 0 1,00
2,00 1,00 0 2,00
3,00 0 0 1,00
4,00 0 0 0
5,00 0 0,50 2,00
6,00 1,00 0 1,00
7,00 0 0 0
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